PA
GOOD

PharVision Advisers’s Gladstone Commercial Corp GOOD Stock Holding History

PharVision Advisers’s Portfolio GOOD Stock Details GOOD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,157
Closed -$140K – 330
2025
Q4 		$140K Sell
13,157
-12,671
-49% -$141K 0.07% 623
2025
Q3 		$318K Sell
25,828
-5,630
-18% -$75K 0.18% 194
2025
Q2 		$451K Buy
31,458
+12,827
+69% +$182K 0.65% 10
2025
Q1 		$279K Buy
18,631
+6,022
+48% +$95K 0.39% 107
2024
Q4 		$205K Buy
+12,609
New +$209K 0.17% 292

Other funds holding GOOD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PharVision Advisers's GOOD Position: Q1 2026 in Review

PharVision Advisers sold out of Gladstone Commercial Corp (GOOD) in Q1 2026, closing a stake of 13,157 shares — an estimated $140K sold.

PharVision Advisers first reported a position in GOOD in Q4 2024 and held it in 5 quarters. The position peaked at $451K in Q2 2025. 204 funds tracked by Wall St. Rank hold GOOD as of Q1 2026.

  • PharVision Advisers reported no remaining Gladstone Commercial Corp position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 13,157 Gladstone Commercial Corp shares in Q1 2026, an estimated $140K.
  • PharVision Advisers first reported a position in Gladstone Commercial Corp in Q4 2024 and held it in 5 quarters.
  • PharVision Advisers's Gladstone Commercial Corp position peaked at $451K in Q2 2025.
  • 204 funds tracked by Wall St. Rank held Gladstone Commercial Corp as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.